Medical Study Innovates New Gene Therapy Technique for Treating Persistent Cystic Fibrosis Mutation

A new gene therapy approach has shown promise in treating cystic fibrosis caused by a specific mutation that does not respond to existing therapies, according to a study coordinated by the University of Trento and published in April 2026.

The research identified a potential treatment for individuals with cystic fibrosis who carry a particular mutation in the CFTR gene and for whom there are currently no approved disease-modifying options. This group represents a subset of patients who do not benefit from widely used CFTR modulator therapies such as Trikafta, which target more common mutations but are ineffective for certain rare variants.

The therapy under investigation delivers a functional copy of the CFTR gene using a modified lentiviral vector designed for inhalation. This approach aims to transfer the gene directly into airway epithelial cells, where the CFTR protein is needed to regulate chloride transport and maintain proper hydration of the airway surface.

Preclinical testing of similar inhaled lentiviral gene therapies has demonstrated sustained expression of the CFTR gene in respiratory cells. In earlier studies, such approaches resulted in CFTR expression in 9–15% of targeted epithelial cells, a level considered sufficient to potentially yield clinical benefit, with effects lasting for at least two years in animal models. These models also showed that repeated dosing was possible without triggering significant immune interference.